International journal of molecular sciences

Transplantation

Diagnostic microbiology and infectious disease

journal of chromatography b, analytical technologies in the biomedical and life sciences

Journal of pharmaceutical and biomedical analysis

Therapeutic drug monitoring

american journal of transplantation : official journal of the american society of transplantation and the american society of transplant surgeons

Clinical chemistry and laboratory medicine

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Chemical research in toxicology

american journal of clinical oncology

Pharmaceutics

digestion

international journal of radiation oncology, biology, physics

expert opinion on pharmacotherapy

expert opinion on drug metabolism & toxicology

biology of blood and marrow transplantation : journal of the american society for blood and marrow transplantation

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

clinical colorectal cancer

scandinavian journal of clinical and laboratory investigation

therapie

Pharmacogenomics

[1] Measurement of sirolimus concentrations in human blood using an automated electrochemiluminescence immunoassay (ECLIA): a multicenter evaluation.

[2] Intrapatient Variability in the Pharmacokinetics of Etanercept Maintenance Treatment.

[3] Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.

[4] Therapeutic Drug Monitoring of Everolimus: A Consensus Report.

[5] Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy.

[6] Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients.

[7] Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†).

[8] Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring.

[9] Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling.

[10] Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.

[11] Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.

[12] [Level of evidence for therapeutic drug monitoring of everolimus].

[13] Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study.

[14] Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

[15] Determination of total, free and saliva mycophenolic acid with a LC-MS/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients.

[16] Mycophenolate blood level monitoring: recent progress.

[17] the routine practice of therapeutic drug monitoring - some of the results of work in the system of chi

[18] vancomycin treatment: analysis of efficacy and safety

[19] Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation.

[20] The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure.

[21] LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring.

[22] Impact of and Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis.

[23] Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring.

[24] A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea

[25] Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience

[26] A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea

[27] A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea

[28] Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience

[29] Suboxone Treatment and Recovery Trial (STAR-T): Study Protocol for a Randomised Controlled Trial of Opioid Medication Assisted Treatment with Adjunctive Medication Management Using Therapeutic Drug Monitoring and Contingency Management

[30] Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.

[31] A new HPLC-MS/MS method for simultaneous determination of Cyclosporine A, Tacrolimus, Sirolimus and Everolimus for routine therapeutic drug monitoring.

[32] Therapeutic drug monitoring of cyclosporine and tacrolimus in Myanmar kidney transplant patients

[33] Combined approach with therapeutic drug monitoring and pharmacogenomics in renal transplant recipients

[34] ["Drug Interaction Stewardship" (DIS) and Therapeutic Drug Monitoring for Anti-infective Treatment in Intensive Care, a Single Centre Observational Study].

[35] Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.

[36] Therapeutic Drug Monitoring of Everolimus: A Consensus Report.

[37] Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring.

[38] [Level of evidence for therapeutic drug monitoring of everolimus].

[39] Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

[40] Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review

[41] Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.

[42] the routine practice of therapeutic drug monitoring - some of the results of work in the system of chi

[43] minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: an integrated approach for multidrug-resistant tuberculosis

[44] therapeutic drug monitoring of the newer anti-epilepsy medications

[45] population-specific limited sampling strategies for therapeutic drug monitoring of mycophenolic acid

[46] early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in virginia, usa

[47] on the road towards strategic application of therapeutic drug monitoring of mycophenolic acid in renal allograft recipients

[48] Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review

[49] Therapeutic drug monitoring of amikacin in septic patients

[50] Therapeutic drug monitoring of anti-infective agents in critically ill patients

[51] Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review

[52] Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation.

[53] The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure.

[54] LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring.

[55] Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring.